Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Eplerenone

Criteria

Inclusion Criteria:

• Male or Female patients who are prescribed Selara tablet for Hypertension.

Exclusion Criteria:

• Subjects who have been prescribed Selara tablet.